Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
โ Scribed by van Haarst, J M W; Baas, P; Manegold, C h; Schouwink, J H; Burgers, J A; de Bruin, H G; Mooi, W J; van Klaveren, R J; de Jonge, M J A; van Meerbeeck, J P
- Book ID
- 109997147
- Publisher
- Nature Publishing Group
- Year
- 2002
- Tongue
- English
- Weight
- 78 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide. Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated.
## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo